Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Hematologic Neoplasms × Azithromycin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

COVID-19 2 Respiratory Sounds 1 Pharmacokinetics 1 Neoplasms 1 Lymphoma, Follicular 1 Hematologic Neoplasms 1 Asthma 1

Interventions

Cyclophosphamide 34 fludarabine 29 Tacrolimus 25 Whole-Body Irradiation 22 Mycophenolic Acid 22 Busulfan 21 fludarabine phosphate 19 Melphalan 16 thymoglobulin 14 Antilymphocyte Serum 14 Thiotepa 11 Methotrexate 11 Stem Cell Transplantation 8 Sirolimus 7 Rituximab 7 Granulocyte Colony-Stimulating Factor 7 Filgrastim 6 trametinib 5 ruxolitinib 4 merphos 4 Nivolumab 4 Cytarabine 4 Cyclosporine 4 Cord Blood Stem Cell Transplantation 4 fedratinib 3 ceritinib 3 angiotensin I (1-7) 3 Radiotherapy 3 Peripheral Blood Stem Cell Transplantation 3 Pentostatin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04392128 2020-09-04

HYACINTHE

Institut de cancérologie Strasbourg Europe

Phase 2 Withdrawn

Other hematologic neoplasm

COVID-19, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡